CARSGEN-B (02171) rose more than 12%, extending its recent gains. At the time of writing, the stock was up 10.78% to HK$15.42, with a turnover of HK$127 million. The company recently released its annual results, reporting revenue of RMB 126 million, a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. The group's revenue primarily came from its product, CT053 (an autologous BCMA CAR-T cell therapy). Notably, revenue for CT053 was calculated based on ex-factory prices rather than end-market prices. On March 9, CARSGEN-B was officially included in the Hong Kong Stock Connect scheme. This inclusion reflects market recognition of the company's core CAR-T business development potential, operational compliance, and stock liquidity, aligning with its long-term development strategy and the fundamental interests of all shareholders. The move is expected to provide mainland investors with more convenient access to the stock, significantly enhancing market attention and liquidity, and injecting strong momentum into the company's capital market development.